Interview of Prof. Meunier for EJC News Focus
6 Mar 2012
Director General Françoise Meunier discusses the challenges faced today by clinical researchers in cancer. She outlines key changes needed in the ongoing revision of the Clinical Trials Directive – in particular, the need for a risk-based approach to trials, and for Member States to harmonise their implementation of the Directive – and she describes the essential features of a suggested new partnership between academia and industry. She also covers the role EORTC will continue to play in developing the early careers of investigators.
Related News
First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer
28 Oct 2026
EORTC at ESMO 2026: New findings and ongoing studies
27 Oct 2026
EORTC research presented at ESMO 2026
22 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
